Erratum: Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine (Brain Tumor Pathol DOI: 10.1007/s10014-012-0124-y);Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine

Brain Tumor Pathology

Volumn 30, Issue 3, 2013, Pages 167-174

  Kato, Yasutaka ^a   Nishihara, Hiroshi ^a   Yuzawa, Sayaka ^a   Mohri, Hiromi ^b   Kanno, Hiromi ^a   Hatanaka, Yutaka ^c   Kimura, Taichi ^a   Tanino, Mishie ^a   Tanaka, Shinya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hokuto Hospital   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Immunohistochemistry; Metastatic brain tumor; Molecular expression profile; Personalized medicine

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ALKYLATING AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE; TUMOR SUPPRESSOR PROTEIN; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; BRAIN; BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SECONDARY; VERY ELDERLY; BRAIN TUMOR; METASTASIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; BRAIN NEOPLASMS; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEINS;

EID: 84880784577     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-013-0143-3     Document Type: Erratum

References (22)

1. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R et al (2012) Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 123:205-222
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyons
3. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA et al (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16:5664-5678
4. Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T et al (2004) Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46:255-261
5. Olson JJ, Paleologos NA, Gaspar LE, Robinson PD, Morris RE, Ammirati M et al (2010) The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 96:115-142
6. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993-1999
7. Jones RL, Smith IE (2004) Efficacy and safety of trastuzumab. Expert Opin Drug Saf 3:317-327
8. Sawaki M, Ito Y, Tada K, Mizunuma N, Takahashi S, Horikoshi N et al (2004) Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori 90:40-43
9. Milas I, Komaki R, Hachiya T, Bubb RS, Ro JY, Langford L et al (2003) Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. Clin Cancer Res 9:1070-1076
10. Italiano A, Saint-Paul MC, Caroli-Bosc FX, Francois E, Bourgeon A, Benchimol D et al (2005) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol 16:1503-1507
11. Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M et al (2008) Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer 113:2129-2138
12. Sihto H, Lundin J, Lundin M, Lehtimaki T, Ristimaki A, Holli K et al (2011) Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res BCR 13:R87
13. Wu PF, Kuo KT, Kuo LT, Lin YT, Lee WC, Lu YS et al (2010) O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer 68:484-490
14. Ingold B, Schraml P, Heppner FL, Moch H (2009) Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS ONE 4:e4775
15. Sasai K, Akagi T, Aoyanagi E, Tabu K, Kaneko S, Tanaka S (2007) O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. Mol Cancer 6:36
16. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L et al (2009) Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 4:1212-1220
17. Yoshida S, Takahashi H (2009) Expression of extracellular matrix molecules in brain metastasis. J Surg Oncol 100:65-68
18. Brandsma D, van den Bent MJ (2007) Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol 19:598-605
19. Jacinto FV, Esteller M (2007) MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair (Amst) 6:1155-1160
20. Rades D, Nadrowitz R, Buchmann I, Hunold P, Noack F, Schild SE et al (2010) Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al.]. 186:458-462
21. Rizzo MT (2011) Cyclooxygenase-2 in oncogenesis. Clinica Chimica Acta Int J Clin Chem 412:671-687
22. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005-1009